Continuation of Dabigatran Therapy in “Real-World” Practice in Hong Kong

• Mei Han Ho,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Chi Wai Ho,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Emmanuel Cheung,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Pak Hei Chan,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Jo Jo Hai,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Koon Ho Chan,

  Affiliation Neurology Division, Department of Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Esther W. Chan,

  Affiliation Department of Pharmacology and Pharmacy, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Gilberto Ka Kit Leung,

  Affiliation Division of Neurosurgery, Department of Surgery, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Hung Fat Tse,

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯
• Chung Wah Siu

  * E-mail: cwdsiu@hku.hk

  Affiliation Cardiology Division, Department of Medicine, Queen Mary Hospital, the University of Hong Kong, Hong Kong SAR, China

  ⨯